Navigation Links
Profil Institute's CEO Presenting on Early Phase Clinical Research in India
Date:1/27/2011

SAN DIEGO, Jan. 27, 2011 /PRNewswire/ -- Profil™ Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, announced today that CEO Dr. Marcus Hompesch is an invited speaker at the Ramanbhai Foundation 5th International Symposium and ISCR's 4th Annual Clinical Research Conference in February.  

The Ramanbhai Foundation's International Symposium will be held February 1-4 in Ahmedabad, India and is hosted by the Zydus Research Center, the research arm of Indian pharmaceutical company Zydus Cadila. The symposium's speakers include world-leading scientists from academia and the pharmaceutical industry specializing in drug research and development for cancer, inflammation, and cardio-metabolic diseases.  Profil Institute's Dr. Hompesch will speak on the topic of selecting the appropriate target populations for early phase clinical research and first in human studies of diabetes drugs.

Dr. Hompesch will also present at the Indian Society for Clinical Research's (ISCR) 4th Annual Clinical Research Conference held February 11-12 at the Crowne Plaza Hotel in Gurgaon, India.  The conference's focus is strengthening India's domestic clinical research industry through best practices, stricter regulatory standards and global partnerships.  Dr. Hompesch will present on the topic of early clinical development in India and its proof of concept in diabetes.  

"Historically India's pharmaceutical companies have focused on providing outsourcing and on competitive manufacturing of generics, APIs, and chemicals used in the manufacturing of drugs," said Dr. Marcus Hompesch, Profil Institute CEO.  "However, healthcare has become a key priority for the Indian government, and we are now seeing a paradigm shift as India strives to bolster its position in the pharmaceutical and clinical research industry as a global partner, innovator and competitor."

India'
'/>"/>

SOURCE Profil Institute for Clinical Research, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reportlinker Adds Teva Pharma. Industries Ltd: PharmaVitae Profile
2. Reportlinker Adds CSL Limited: PharmaVitae Profile
3. Reportlinker Adds UCB S.A.: PharmaVitae Profile
4. Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile
5. Reportlinker Adds H. Lundbeck A/S: PharmaVitae Profile
6. Reportlinker Adds Daiichi Sankyo Co., Ltd: PharmaVitae Profile
7. Reportlinker Adds Merck & Co., Inc.: PharmaVitae Profile
8. Reportlinker Adds Shire plc: PharmaVitae Profile
9. Reportlinker Adds Novo Nordisk A/S: PharmaVitae Profile
10. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
11. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Israel, Aug. 31, 2015  Chiasma, Inc. (NASDAQ: ... developing octreotide capsules for the orphan condition acromegaly, ... ended June 30, 2015 and provided a corporate ... been a transformative time for Chiasma, as we ... announced that our first New Drug Application (NDA) ...
(Date:8/31/2015)... , August 31, 2015 ... that the global cardiovascular monitoring and diagnostic devices ... is predicted to reach a value of approximately ... of 9.7% between 2013 and 2019. The title ... Devices Market (ECG, Holter Monitors, Event Monitors, Cardiovascular ...
(Date:8/31/2015)... NEW YORK , Aug. 31, 2015  Dipexium ... company focused on the development and commercialization of Locilex® ... peptide, today announced plans to participate in four investor ... September 2, 2015 at the Sidoti & Company, LLC ... City . David P. Luci , President ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... YORK, July 8, 2011 The U.S. Food and ... Diphtheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed (Tdap)] for ... for active booster immunization against tetanus, diphtheria and pertussis ... vaccine approved for use in this age group.  With ...
... July 8, 2011 /PRNewswire-Asia/ -- Shenzhen Wuzhou Changlian International ... of multifunctional medical and industrial products, is pleased to ... Up to a 35% discount will be offered in ... promotional activity range from infrared thermometers , digital ...
Cached Medicine Technology:GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 2GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 3GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 4Enjoy Only One Thermometer in Various Domains 2
(Date:9/1/2015)... ... September 01, 2015 , ... Mercy Health (formerly Catholic Health ... 10th of its monthly Mercy Health: Helping You Be Well videos to prostate cancer ... men. , In a concise video on Mercy Health’s YouTube channel, Mercy Health ...
(Date:9/1/2015)... Beach, FL (PRWEB) , ... September 01, 2015 ... ... pharmacy discount cards, launched its consumer-friendly, informational video this week to coincide with ... http://www.USAMedicalCard.com/video . , According to the CDC, elementary school children are ...
(Date:9/1/2015)... ... 01, 2015 , ... Dr. Trace Curry successfully placed one of the first ... last month the FDA has approved two intra-gastric balloons, the ORBERA ™ Managed ... first incisionless, reversible, weight loss procedures available to Americans. , Dr. Curry, ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... and pick-up artists about their experiences of female beauty, women’s emotions, fertility, female ... penis issues, as well as their relationships with other men, documenting how the ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new episode of “Voices In America”, hosted ... at the topic of arthritis. There are over 100 different types of arthritis. One ... and statistics in an effort to shed light on this important topic. , Anyone ...
Breaking Medicine News(10 mins):Health News:New Mercy Health Video Explains Most-Common Cancer Found in Men 2Health News:USA Medical Card Launches New FAQ Video During Back-to-School 2Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2
... mark, but numbers aren,t as high as some might suspect, ... risk of relapse can linger for some breast cancer survivors ... therapy, a new study found. , But, as gloomy as ... risk may not be as dire as many women fear. ...
... Urged to End Role as It Did with ... For the second time in,recent weeks, international ... to withdraw its sponsorship and promotion of a ... company,s activities appear,to violate national law., Last ...
... 12 Smart Balance, Inc.,(Nasdaq: SMBL ) announced ... Balance, Inc., will make a presentation at the Canaccord,Adams ... EDT on Thursday,August 14, 2008., Smart Balance,s presentation ... will be able to ask questions, but,listeners will be ...
... settle question about best treatment for the disease , , ... from a European study that has followed men with ... debate about the advantages of aggressive treatment versus "watchful ... men who underwent surgery to remove the prostate disappeared ...
... Aug. 12 Holland America Line has surpassed the,million-dollar ... the,Cure(R) via its On Deck for the Cure program, ... The line will celebrate the milestone,this week with special ... at its corporate headquarters in Seattle., Since the ...
... Minn. -- Online Internet shopping today offers many benefits. ... your own home and purchase most anything by clicking ... prescription drugs via the Internet, bypassing a traditional office ... issue of Mayo Clinic Proceedings , researchers from ...
Cached Medicine News:Health News:Risk of Breast Cancer Relapse Can Linger 2Health News:Risk of Breast Cancer Relapse Can Linger 3Health News:Philip Morris International Caught in Philippines in Another Concert Sponsorship 2Health News:Philip Morris International Caught in Philippines in Another Concert Sponsorship 3Health News:Smart Balance to Webcast Presentation at Canaccord Adams Global Growth Conference 2Health News:Surgery Helps With Prostate Cancer, Sometimes 2Health News:Surgery Helps With Prostate Cancer, Sometimes 3Health News:Holland America Line Program Surpasses $1 Million Raised for Susan G. Komen for the Cure(R) 2Health News:Holland America Line Program Surpasses $1 Million Raised for Susan G. Komen for the Cure(R) 3Health News:Holland America Line Program Surpasses $1 Million Raised for Susan G. Komen for the Cure(R) 4Health News:Researchers examine safety of Internet prescriber service providing erectile dysfunction medications 2
... EX is a rigid gas lens with ... specific characteristics as hard contact lens, it ... excellent performance against astigmatism. The key feature ... combination of fluoromethacrylate, Siloxanylmethacrylate and methacrylic acid, ...
Achievement, available exclusively from Art Optical, is a unique RGP lens design with a patented junctionless back surface and a controlled edge lift....
... Lifestyle Gp is a ... multi-aspheric back surface. Through a ... surface curves, the LifeStyle Gp ... of add. Plus, its multi-aspheric ...
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach....
Medicine Products: